Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations

Medical Xpress - latest medical and health news stories · 1h ago

The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enzalutamide alone in patients with high-tumor-burden metastatic prostate cancer who had not…

Read original article on Medical Xpress - latest medical and health news stories →

Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations

Related news